| Registry | NCT07741695, acronym PS-CLL016 |
|---|---|
| Status | Not yet recruiting |
| Study type | Observational |
| Enrollment | 50 (Estimated) |
| Sponsor | IRCCS San Raffaele (Other) |
| Conditions | Chronic Lymphocytic Leukemia (CLL) |
| Interventions | Peripheral blood sample collection (Procedure) |
| Dates | start 2026-09-01 (estimated), primary completion 2027-09-01 (estimated), completion 2027-09-01 (estimated), first posted 2026-08-03, last updated 2026-08-04 |
Related Papers Related Patents Related Grants Related Experts
All trials for Chronic Lymphocytic Leukemia (CLL) All trials of Peripheral blood sample collection
Patients with chronic lymphocytic leukemia (CLL) followed at Strategic Research Program on CLL will be enrolled and undergo sampling of additional amount of blood at the time of standard blood tests. Leukemic B cells and peripheral blood mononuclear cells (PBMC).
Patients with chronic lymphocytic leukemia (CLL) followed at Strategic Research Program on CLL will be enrolled and undergo sampling of additional amount of blood at the time of standard blood tests. Leukemic B cells and peripheral blood mononuclear cells (PBMC). Up to 50 ml of blood will be collected for the research project at the time of standard blood tests.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Study cohort | Procedure: Peripheral blood sample collection | Collection of peripheral blood (up to 50 ml) for the analysis of the biological activity of IRAK4 Chimeric Degradation Activation Compound (CDAC) in purified CLL B cells, assessed by changes in proliferation, apoptosis, and signaling pathway activation following in vitro treatment. |
Sex: All, ages: 18 Years to any
Inclusion Criteria: * Age ≥18 years * Diagnosis of CLL * Participant is willing and able to give informed consent for participation in the study. Exclusion Criteria: \- Participant is unable or unwilling to provide informed consent for participation in the study